{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:15:42Z","timestamp":1776435342659,"version":"3.51.2"},"reference-count":170,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.addr.2004.08.008","type":"journal-article","created":{"date-parts":[[2004,9,30]],"date-time":"2004-09-30T15:17:41Z","timestamp":1096557461000},"page":"281-302","source":"Crossref","is-referenced-by-count":69,"title":["Mesalamine delivery systems: do they really make much difference?"],"prefix":"10.1016","volume":"57","author":[{"given":"Altamash I.","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2004.08.008_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0016-5085(92)91096-M","article-title":"Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis","volume":"103","author":"Cominelli","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/gut.33.7.929","article-title":"Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation","volume":"33","author":"Rachmilewitz","year":"1992","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/gut.32.1.50","article-title":"5-aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease","volume":"32","author":"Mahida","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0162-3109(90)90037-F","article-title":"Sulfasalazine inhibits the binding of TNF alpha to its receptor","volume":"20","author":"Shanahan","year":"1990","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.addr.2004.08.008_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0090-6980(76)90145-3","article-title":"Inhibition of prostaglandin biosynthesis by sulphasalazine and its metabolites","volume":"11","author":"Collier","year":"1976","journal-title":"Prostaglandins"},{"key":"10.1016\/j.addr.2004.08.008_bib6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0016-5085(19)31672-5","article-title":"Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine","volume":"75","author":"Sharon","year":"1978","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1172\/JCI110474","article-title":"Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils","volume":"69","author":"Stenson","year":"1982","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2004.08.008_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/00365529009091903","article-title":"Role of eicosanoids as mediators of inflammation in inflammatory bowel disease","volume":"172","author":"Stenson","year":"1990","journal-title":"Scand. J. Gastroenterol., Suppl."},{"key":"10.1016\/j.addr.2004.08.008_bib9","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJM198012253032602","article-title":"Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease","volume":"303","author":"Klotz","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2004.08.008_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/0016-5085(86)90684-0","article-title":"Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis","volume":"91","author":"Lauritsen","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib11","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1016\/0006-2952(87)90028-1","article-title":"The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects?","volume":"36","author":"Aruoma","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2004.08.008_bib12","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/0006-2952(87)90518-1","article-title":"5-Aminosalicylate: oxidation by activated leukocytes and protection of cultured cells from oxidative damage","volume":"36","author":"Dull","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2004.08.008_bib13","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/0016-5085(90)90329-Y","article-title":"Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid","volume":"98","author":"Ahnfelt-Ronne","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0006-2952(91)90207-L","article-title":"Scavenging effect of 5-aminosalicylic acid on neutrophil-derived oxidants. Possible contribution to the mechanism of action in inflammatory bowel disease","volume":"41","author":"Tamai","year":"1991","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2004.08.008_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0092-8674(89)90833-7","article-title":"NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control","volume":"58","author":"Lenardo","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.addr.2004.08.008_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0092-8674(00)81318-5","article-title":"NF-kappa B: ten years after","volume":"87","author":"Baeuerle","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.addr.2004.08.008_bib17","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","article-title":"Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases","volume":"336","author":"Barnes","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2004.08.008_bib18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0016-5085(98)70202-1","article-title":"Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa","volume":"115","author":"Rogler","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib19","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0016-5085(99)70182-4","article-title":"Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes","volume":"116","author":"Kaiser","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/cpt1972134539","article-title":"Absorption, metabolism, and excretion of salicylazosulfapyridine in man","volume":"13","author":"Schroder","year":"1972","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.008_bib21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/gut.34.5.669","article-title":"Oroileal transit of slow release 5-aminosalicylic acid","volume":"34","author":"Goebell","year":"1993","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib22","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/0016-5085(95)90691-6","article-title":"Delivery and fate of oral mesalamine microgranules within the human small intestine","volume":"108","author":"Layer","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2036.2003.01408.x","article-title":"Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis","volume":"17","author":"Sandborn","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.008_bib24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.0954-6820.1942.tb06841.x","article-title":"Salazopyrin: a new sulfanilamide preparation","volume":"110","author":"Svartz","year":"1942","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.addr.2004.08.008_bib25","first-page":"366","article-title":"Response of ulcerative colitis to therapy with salicylazosulfapyridine","volume":"151","author":"Morrison","year":"1953","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.addr.2004.08.008_bib26","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(62)92080-9","article-title":"Sulphasalazine and salicylazosulphadimidine in ulcerative colitis","volume":"1","author":"Baron","year":"1962","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2004.08.008_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/jmg.9.2.168","article-title":"The polymorphic acetylation of sulphapyridine in man","volume":"9","author":"Schroder","year":"1972","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.addr.2004.08.008_bib28","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0016-5085(73)80035-6","article-title":"Distribution studies of salicylazosulfapyridine and its metabolites","volume":"64","author":"Peppercorn","year":"1973","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2165\/00003088-197601060-00002","article-title":"Clinical pharmacokinetics of sulphasalazine","volume":"1","author":"Das","year":"1976","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2004.08.008_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-198510040-00001","article-title":"Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid","volume":"10","author":"Klotz","year":"1985","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2004.08.008_bib31","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3109\/00365528909090784","article-title":"Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers","volume":"24","author":"Rijk","year":"1989","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.7326\/0003-4819-51-5-879","article-title":"A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis","volume":"51","author":"Moertel","year":"1959","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2004.08.008_bib33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/gut.5.5.437","article-title":"Controlled trial of sulphasalazine in the treatment of ulcerative colitis","volume":"50","author":"Dick","year":"1964","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/gut.14.12.923","article-title":"A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin)","volume":"14","author":"Dissanayake","year":"1973","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib35","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/gut.21.3.232","article-title":"Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis","volume":"21","author":"Azad Khan","year":"1980","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/00365521.1973.12096672","article-title":"The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A double-blind trial on patients asymptomatic for one year","volume":"8","author":"Riis","year":"1973","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib37","first-page":"1456","article-title":"Maintenance oral sulfasalazine prolongs remission in ulcerative proctitis and proctosigmoiditis","volume":"86","author":"La Rosa","year":"1991","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib38","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib40","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/0016-5085(79)90388-3","article-title":"A trial of sulfasalazine as adjunctive therapy in Crohn's disease","volume":"77","author":"Singleton","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-114-6-445","article-title":"Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial","volume":"114","author":"Rijk","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2004.08.008_bib42","doi-asserted-by":"crossref","first-page":"377","DOI":"10.7326\/0003-4819-101-3-377","article-title":"Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development","volume":"101","author":"Peppercorn","year":"1984","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2004.08.008_bib43","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1136\/bmj.2.5321.1708","article-title":"Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis","volume":"5321","author":"Truelove","year":"1962","journal-title":"Br. Med. J."},{"key":"10.1016\/j.addr.2004.08.008_bib44","first-page":"2707","volume":"vol. 58","author":"Azulfidine EN tabs\u00ae","year":"2004"},{"key":"10.1016\/j.addr.2004.08.008_bib45","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/gut.22.6.452","article-title":"Incidence of sulphasalazine-induced male infertility","volume":"22","author":"Birnie","year":"1981","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib46","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(79)90292-7","article-title":"Male infertility due to sulphasalazine","volume":"2","author":"Levi","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2004.08.008_bib47","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0140-6736(79)92718-1","article-title":"Male infertility due to sulphasalazine","volume":"2","author":"Toth","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2004.08.008_bib48","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0140-6736(79)91512-5","article-title":"Male infertility due to sulphasalazine","volume":"2","author":"Grieve","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2004.08.008_bib49","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(79)91702-1","article-title":"Male infertility due to sulphasalazine","volume":"2","author":"Traub","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2004.08.008_bib50","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM197309062891001","article-title":"Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype","volume":"289","author":"Das","year":"1973","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2004.08.008_bib51","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/BF01296907","article-title":"Sulfasalazine. Adverse effects and desensitization","volume":"28","author":"Taffet","year":"1983","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.addr.2004.08.008_bib52","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1136\/bmj.2.6204.1553","article-title":"Placental and mammary transfer of sulphasalazine","volume":"2","author":"Khan","year":"1979","journal-title":"Br. Med. J."},{"key":"10.1016\/j.addr.2004.08.008_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00365528209181034","article-title":"Fertility, sterility, and pregnancy in chronic inflammatory bowel disease","volume":"17","author":"Jarnerot","year":"1982","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib54","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3109\/00365527909181418","article-title":"Sulphasalazine treatment during breast feeding","volume":"14","author":"Jarnerot","year":"1979","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib55","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2165\/00003495-199141040-00009","article-title":"Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease","volume":"41","author":"Wadworth","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2004.08.008_bib56","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3109\/00365528309181640","article-title":"Absorption and excretion of azodisal sodium and its metabolites in man after rectal administration of a single 2-g dose","volume":"18","author":"Sandberg-Gertzen","year":"1983","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib57","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/gut.23.12.1081","article-title":"Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis","volume":"23","author":"Willoughby","year":"1982","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib58","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/bmj.291.6506.1373","article-title":"Olsalazine in active ulcerative colitis","volume":"291","author":"Selby","year":"1985","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.addr.2004.08.008_bib59","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/00365528809101552","article-title":"Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition","volume":"148","author":"Hetzel","year":"1988","journal-title":"Scand. J. Gastroenterol., Suppl."},{"key":"10.1016\/j.addr.2004.08.008_bib60","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/gut.30.5.675","article-title":"Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study","volume":"30","author":"Rao","year":"1989","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib61","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/00365528809101553","article-title":"Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects","volume":"148","author":"Ewe","year":"1988","journal-title":"Scand. J. Gastroenterol., Suppl."},{"key":"10.1016\/j.addr.2004.08.008_bib62","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2036.1998.00360.x","article-title":"Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis","volume":"12","author":"Kruis","year":"1998","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.008_bib63","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/0016-5085(86)90882-6","article-title":"Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties","volume":"90","author":"Sandberg-Gertzen","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib64","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/gut.35.9.1282","article-title":"Optimum dose of olsalazine for maintaining remission in ulcerative colitis","volume":"35","author":"Travis","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib65","first-page":"391","article-title":"Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis","volume":"7","author":"Kruis","year":"1995","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2004.08.008_bib66","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/gut.29.6.835","article-title":"Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis","volume":"29","author":"Ireland","year":"1988","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib67","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/gut.49.4.552","article-title":"Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study","volume":"49","author":"Mahmud","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib68","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/gut.29.7.974","article-title":"Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis","volume":"29","author":"Lauritsen","year":"1988","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib69","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3109\/00365528708991953","article-title":"Olsalazine in patients intolerant of sulphasalazine","volume":"22","author":"Ireland","year":"1987","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib70","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/gut.28.3.346","article-title":"Effects of olsalazine in the jejunum of the rat","volume":"28","author":"Mohsen","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib71","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/0016-5085(88)90172-2","article-title":"Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid","volume":"95","author":"Pamukcu","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib72","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/gut.32.3.270","article-title":"Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects","volume":"32","author":"Raimundo","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib73","first-page":"1130","volume":"vol. 58","author":"Dipentum\u00ae","year":"2004"},{"key":"10.1016\/j.addr.2004.08.008_bib74","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/BF01299921","article-title":"Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide","volume":"28","author":"Chan","year":"1983","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.addr.2004.08.008_bib75","first-page":"2996","volume":"vol. 58","author":"Colazal\u2122","year":"2004"},{"key":"10.1016\/j.addr.2004.08.008_bib76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0016-5085(98)70627-4","article-title":"Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group","volume":"114","author":"Green","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib77","first-page":"1398","article-title":"A randomized, double blind, dose\u2013response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis","volume":"97","author":"Levine","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib78","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1111\/j.1572-0241.2002.07103.x","article-title":"Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis","volume":"97","author":"Pruitt","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib79","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.1365-2036.2002.01150.x","article-title":"A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis","volume":"16","author":"Green","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.008_bib80","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2036.2002.01151.x","article-title":"A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis","volume":"16","author":"Mansfield","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.008_bib81","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2036.1992.tb00561.x","article-title":"Improved maintenance of remission in ulcerative colitis by balsalazide 4 g\/day compared with 2 g\/day","volume":"6","author":"Giaffer","year":"1992","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.008_bib82","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/gut.49.6.783","article-title":"Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses","volume":"49","author":"Kruis","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib83","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2036.1992.tb00578.x","article-title":"Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months","volume":"6","author":"Green","year":"1992","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.008_bib84","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2036.1988.tb00693.x","article-title":"Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine","volume":"2","author":"McIntyre","year":"1988","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.008_bib85","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1046\/j.1365-2036.1998.00427.x","article-title":"Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group","volume":"12","author":"Green","year":"1998","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.008_bib86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2125.1983.tb04983.x","article-title":"Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis","volume":"16","author":"Dew","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2004.08.008_bib87","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2125.1982.tb01999.x","article-title":"An oral preparation to release drugs in the human colon","volume":"14","author":"Dew","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2004.08.008_bib88","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/gut.28.2.196","article-title":"Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract","volume":"28","author":"Myers","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib89","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2036.1990.tb00499.x","article-title":"Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man","volume":"4","author":"Christensen","year":"1990","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.008_bib90","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/gut.28.9.1084","article-title":"Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis","volume":"28","author":"Mardini","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib91","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/00365529009095533","article-title":"Absorption of oral mesalazine-containing preparations and the influence of famotidine on the absorption","volume":"25","author":"Wiltink","year":"1990","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib92","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1365-2125.1998.00762.x","article-title":"Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration","volume":"46","author":"Hussain","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2004.08.008_bib93","first-page":"1","article-title":"A scintigraphic study to evaluate what happens to Pentasa\u00ae and Asacol\u00ae in the human gut","author":"Wilding","year":"1999","journal-title":"Pract. Gastroenterol., Suppl."},{"key":"10.1016\/j.addr.2004.08.008_bib94","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7326\/0003-4819-115-5-350","article-title":"Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study","volume":"115","author":"Sninsky","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2004.08.008_bib95","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2004.08.008_bib96","doi-asserted-by":"crossref","first-page":"204","DOI":"10.7326\/0003-4819-124-2-199601150-00003","article-title":"An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group","volume":"124","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2004.08.008_bib97","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/bmj.287.6384.23","article-title":"Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth","volume":"287","author":"Dew","year":"1983","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.addr.2004.08.008_bib98","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/bmj.285.6347.1012","article-title":"Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid","volume":"285","author":"Dew","year":"1982","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.addr.2004.08.008_bib99","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/0016-5085(88)90677-4","article-title":"Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis","volume":"94","author":"Riley","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib100","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0016-5085(99)70172-1","article-title":"Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial","volume":"116","author":"Prantera","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib101","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2036.2003.01462.x","article-title":"Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial","volume":"17","author":"Caprilli","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.008_bib102","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2036.1999.00501.x","article-title":"Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. Gruppo Italiano per lo Studio del Colon e del Retto","volume":"13","author":"Frieri","year":"1999","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.008_bib103","first-page":"2829","volume":"vol. 58","author":"Asacol\u00ae","year":"2004"},{"key":"10.1016\/j.addr.2004.08.008_bib104","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0016-5085(82)80075-9","article-title":"5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans","volume":"83","author":"Rasmussen","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib105","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/j.1552-4604.1993.tb05612.x","article-title":"Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy","volume":"33","author":"Hardy","year":"1993","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2004.08.008_bib106","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200039020-00001","article-title":"Clinical pharmacokinetics of slow release mesalazine","volume":"39","author":"De Vos","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2004.08.008_bib107","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2036.1995.tb00387.x","article-title":"Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine","volume":"9","author":"Larouche","year":"1995","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.008_bib108","first-page":"1188","article-title":"Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group","volume":"88","author":"Hanauer","year":"1993","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib109","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/gut.29.5.669","article-title":"Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse","volume":"29","author":"Riley","year":"1988","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib110","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/BF02065413","article-title":"Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group","volume":"40","author":"Miner","year":"1995","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.addr.2004.08.008_bib111","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0016-5085(88)80061-1","article-title":"Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis","volume":"95","author":"Mulder","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib112","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3109\/00365528708991929","article-title":"5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa","volume":"22","author":"Rasmussen","year":"1987","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib113","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0016-5085(93)90337-C","article-title":"Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group","volume":"104","author":"Singleton","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib114","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0016-5085(93)90411-5","article-title":"Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID)","volume":"104","author":"Gendre","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib115","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1053\/gast.1996.v110.pm8608877","article-title":"Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives","volume":"110","author":"Modigliani","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib116","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0016-5085(95)90059-4","article-title":"Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group","volume":"108","author":"Brignola","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib117","first-page":"3153","volume":"vol. 58","author":"Pentasa\u00ae","year":"2004"},{"key":"10.1016\/j.addr.2004.08.008_bib118","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/bmj.2.5104.1072","article-title":"Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial","volume":"14","author":"Truelove","year":"1958","journal-title":"Br. Med. J."},{"key":"10.1016\/j.addr.2004.08.008_bib119","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(77)90831-5","article-title":"An experiment to determine the active therapeutic moiety of sulphasalazine","volume":"2","author":"Azad Khan","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2004.08.008_bib120","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/gut.21.7.632","article-title":"Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine","volume":"21","author":"van Hees","year":"1980","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib121","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1365-2036.2003.01409.x","article-title":"Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients","volume":"17","author":"Aumais","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.008_bib122","doi-asserted-by":"crossref","first-page":"71S","DOI":"10.1007\/BF01312468","article-title":"Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99 mTc-labeled 5-ASA suppositories","volume":"32","author":"Williams","year":"1987","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.addr.2004.08.008_bib123","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3109\/00365529108996497","article-title":"Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions","volume":"26","author":"Jacobsen","year":"1991","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib124","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF00298473","article-title":"Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial","volume":"5","author":"Campieri","year":"1990","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.addr.2004.08.008_bib125","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/00365529009091913","article-title":"Role of rectal formulations: suppositories","volume":"172","author":"Williams","year":"1990","journal-title":"Scand. J. Gastroenterol., Suppl."},{"key":"10.1016\/j.addr.2004.08.008_bib126","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/BF02563691","article-title":"5-Aminosalicylic acid suppositories in the management of ulcerative colitis","volume":"32","author":"Campieri","year":"1989","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.addr.2004.08.008_bib127","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3109\/00365529008997590","article-title":"Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial","volume":"25","author":"Campieri","year":"1990","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib128","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/00004836-198808000-00012","article-title":"5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis?","volume":"10","author":"Campieri","year":"1988","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF02236902","article-title":"Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis","volume":"41","author":"Gionchetti","year":"1998","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.addr.2004.08.008_bib130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/00365529509093256","article-title":"Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens","volume":"30","author":"Farup","year":"1995","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib131","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1572-0241.1998.228_a.x","article-title":"Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group","volume":"93","author":"d'Albasio","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib132","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1572-0241.2000.02185.x","article-title":"Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis","volume":"95","author":"Hanauer","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib133","first-page":"795","volume":"vol. 58","author":"Canasa\u2122","year":"2004"},{"key":"10.1016\/j.addr.2004.08.008_bib134","first-page":"3173","volume":"vol. 58","author":"Rowasa\u00ae","year":"2004"},{"key":"10.1016\/j.addr.2004.08.008_bib135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0025-6196(12)60100-1","article-title":"Distribution of mesalamine enemas in patients with active distal ulcerative colitis","volume":"67","author":"Chapman","year":"1992","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.addr.2004.08.008_bib136","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1007\/BF01540060","article-title":"Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis","volume":"34","author":"Vitti","year":"1989","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.addr.2004.08.008_bib137","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/00003088-199120030-00006","article-title":"Retrograde spread of mesalazine (5-aminosalicylic acid)-containing enema in patients with ulcerative colitis","volume":"20","author":"Tiel-van Buul","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2004.08.008_bib138","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/gut.26.4.400","article-title":"Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion","volume":"26","author":"Campieri","year":"1985","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib139","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/gut.32.8.929","article-title":"Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis","volume":"32","author":"Campieri","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ibd.3780040202","article-title":"Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group","volume":"4","author":"Hanauer","year":"1998","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.addr.2004.08.008_bib141","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/0016-5085(87)90621-4","article-title":"5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis","volume":"92","author":"Sutherland","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib142","first-page":"1867","article-title":"A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis","volume":"92","author":"Safdi","year":"1997","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib143","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00042737-199606000-00010","article-title":"Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg\/2 g) as retention enemas in active ulcerative proctitis","volume":"8","author":"Mulder","year":"1996","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2004.08.008_bib144","first-page":"1338","article-title":"A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults","volume":"91","author":"Kam","year":"1996","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib145","first-page":"412","article-title":"5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial","volume":"81","author":"Friedman","year":"1986","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib146","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0016-5085(90)91237-Z","article-title":"Long-term use of mesalamine enemas to induce remission in ulcerative colitis","volume":"99","author":"Biddle","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib147","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0016-5085(88)90569-0","article-title":"5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis","volume":"94","author":"Biddle","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib148","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/BF02156265","article-title":"Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis","volume":"33","author":"d'Albasio","year":"1990","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.addr.2004.08.008_bib149","first-page":"1143","article-title":"Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study","volume":"92","author":"d'Albasio","year":"1997","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib150","first-page":"2201","article-title":"Safety of topical 5-aminosalicylic acid in pregnancy","volume":"92","author":"Bell","year":"1997","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib151","first-page":"210","article-title":"The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review","volume":"3","author":"Kane","year":"2003","journal-title":"Rev. Gastroenterol. Disord."},{"key":"10.1016\/j.addr.2004.08.008_bib152","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/09629359891027","article-title":"Drug therapy: dose\u2013response relationship of oral mesalazine in inflammatory bowel disease","volume":"7","author":"Mulder","year":"1998","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.addr.2004.08.008_bib153","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1572-0241.2001.04683.x","article-title":"Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis","volume":"96","author":"Kane","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib154","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","author":"Kane","year":"2003","journal-title":"Am. J. Med."},{"key":"10.1016\/j.addr.2004.08.008_bib155","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00004836-200102000-00019","article-title":"Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine","volume":"32","author":"Margetts","year":"2001","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib156","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000064461","article-title":"Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease","volume":"92","author":"Frandsen","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.addr.2004.08.008_bib157","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/gut.51.4.536","article-title":"Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines","volume":"51","author":"Ransford","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.008_bib158","first-page":"265","article-title":"Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease","volume":"49","author":"Calvino","year":"1998","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.addr.2004.08.008_bib159","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0016-5085(93)90715-O","article-title":"Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis","volume":"105","author":"Choi","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib160","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1053\/gast.2001.22449","article-title":"Screening and surveillance colonoscopy in chronic Crohn's colitis","volume":"120","author":"Friedman","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib161","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/gast.2003.1240574","article-title":"The mesalamine wars heat up-enter balsalazide","volume":"124","author":"Cohen","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.008_bib162","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/j.1572-0241.2002.05763.x","article-title":"Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges?","volume":"97","author":"Farrell","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib163","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1111\/j.1572-0241.2002.07092.x","article-title":"Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis","volume":"97","author":"Sandborn","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib164","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1572-0241.2003.07205.x","article-title":"Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis","volume":"98","author":"Hanauer","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib165","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1572-0241.2003.07204.x","article-title":"Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercorn and letter to the editor by Dr. Hanauer","volume":"98","author":"Johnson","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib166","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1572-0241.2003.07323.x","article-title":"Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt","volume":"98","author":"Hanauer","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.008_bib167","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2004.08.008_bib168","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.274.18.1456","article-title":"Subverting randomization in controlled trials","volume":"274","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2004.08.008_bib169","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.273.5.408","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2004.08.008_bib170","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1572-0241.2000.01940.x","article-title":"A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis","volume":"95","author":"Cohen","year":"2000","journal-title":"Am. J. Gastroenterol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X0400198X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X0400198X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T02:37:43Z","timestamp":1624675063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X0400198X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":170,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0169409X0400198X"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2004.08.008","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}